On October 24, 2023, the Board of Directors of Quince Therapeutics, Inc. appointed Brendan Hannah to the position of Chief Operating Officer of the Company. Mr. Hannah will continue to serve as Chief Business Officer and the principal financial officer and principal accounting officer of the Company. Brendan Hannah, age 38, has served as the Company?s Chief Business Officer since May 2022, and as Company?s principal financial officer and principal accounting officer since March 2023.

Previously, Mr. Hannah served as the Chief Operating Officer of Novosteo Inc., a biopharmaceutical company, from November 2021 to May 2022. Previously, Mr. Hannah was the Chief Business Officer of Neuroptika, Inc., a biopharmaceutical company, from January 2019 to October 2021, and as the Co-Founder and Vice President of Operations and Strategy of Geom Therapeutics, a biopharmaceutical company, from January 2017 to March 2020. Mr. Hannah was the Head of Corporate Development at Agenovir Corporation from January 2017 to January 2018.

Mr. Hannah holds an M.B. A from the University of California, Los Angeles Anderson School of Management and a B.A. in Economics from Colorado College. In connection with his appointment as Chief Operating Officer, the Compensation Committee of the Board of Directors of the Company granted Mr. Hannah an option to purchase 75,000 shares of the Company?s Common Stock (the ?Option?) pursuant to the Company?s 2019 Equity Incentive Plan, at an exercise price per share equal to $0.99, the fair market value of the Company?s Common Stock on the grant date. The total number of shares subject to the Option will vest in 48 equal monthly installments from the vesting commencement date of October 23, 2023, subject to Mr. Hannah?s continuous service with the Company through each applicable vesting date.